The Manufacturers Life Insurance Company Invests $534,000 in Alto Neuroscience, Inc. $ANRO

The Manufacturers Life Insurance Company bought a new position in shares of Alto Neuroscience, Inc. (NYSE:ANRO) in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 23,747 shares of the company’s stock, valued at approximately $534,000. The Manufacturers Life Insurance Company owned about 0.07% of Alto Neuroscience at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in the business. Quantinno Capital Management LP increased its stake in Alto Neuroscience by 1.4% in the 1st quarter. Quantinno Capital Management LP now owns 36,069 shares of the company’s stock valued at $811,000 after buying an additional 490 shares during the last quarter. Torren Management LLC bought a new stake in Alto Neuroscience during the 4th quarter worth about $62,000. XTX Topco Ltd boosted its stake in shares of Alto Neuroscience by 32.2% during the 4th quarter. XTX Topco Ltd now owns 20,824 shares of the company’s stock worth $371,000 after buying an additional 5,078 shares during the last quarter. Renaissance Technologies LLC boosted its stake in shares of Alto Neuroscience by 6.3% during the 1st quarter. Renaissance Technologies LLC now owns 103,499 shares of the company’s stock worth $2,327,000 after buying an additional 6,100 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its holdings in shares of Alto Neuroscience by 26.1% in the 1st quarter. Dimensional Fund Advisors LP now owns 39,324 shares of the company’s stock valued at $884,000 after acquiring an additional 8,148 shares in the last quarter.

Alto Neuroscience Trading Down 0.5%

Shares of NYSE:ANRO opened at $32.14 on Friday. Alto Neuroscience, Inc. has a 52-week low of $3.05 and a 52-week high of $33.67. The company has a market capitalization of $1.13 billion, a P/E ratio of -13.28 and a beta of 1.06. The company has a 50-day simple moving average of $25.97 and a 200 day simple moving average of $22.75. The company has a debt-to-equity ratio of 0.07, a quick ratio of 20.52 and a current ratio of 14.85.

Alto Neuroscience (NYSE:ANRO) last posted its quarterly earnings results on Wednesday, August 12th. The company reported ($0.65) EPS for the quarter, topping analysts’ consensus estimates of ($0.73) by $0.08. Sell-side analysts forecast that Alto Neuroscience, Inc. will post -3.14 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on ANRO. BTIG Research lifted their target price on Alto Neuroscience from $28.00 to $37.00 and gave the company a “buy” rating in a research report on Thursday. Robert W. Baird reduced their price target on Alto Neuroscience from $38.00 to $36.00 and set an “outperform” rating for the company in a research report on Monday, May 18th. Zacks Research downgraded Alto Neuroscience from a “hold” rating to a “strong sell” rating in a research note on Wednesday, July 22nd. Chardan Capital reaffirmed a “buy” rating and set a $30.00 price target on shares of Alto Neuroscience in a research report on Wednesday, April 22nd. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Alto Neuroscience in a research note on Wednesday, July 29th. Eight research analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $36.62.

About Alto Neuroscience

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.